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Abstract
The process of autophagy and its role in survival of human neuroblastoma cell cultures was studied upon addition of an 
anti-GD2 ganglioside (GD2) 14G2a mouse monoclonal antibody (14G2a mAb) and an aurora A kinase specific inhibitor, 
MK-5108. It was recently shown that combination of these agents significantly potentiates cytotoxicity against IMR-32 and 
CHP-134 neuroblastoma cells in vitro, as compared to the inhibitor used alone. In this study we gained mechanistic insights 
on autophagy in the observed cytotoxic effects exerted by both agents using cytotoxicity assays, RT-qPCR, immunoblotting, 
and autophagy detection methods. Enhancement of the autophagy process in the 14G2a mAb- and MK-5108-treated IMR-32 
cells was documented by assessing autophagic flux. Application of a lysosomotropic agent—chloroquine (CQ) affected the 
14G2a mAb- and MK-5108-stimulated autophagic flux. It is our conclusion that the 14G2a mAb (40 μg/ml) and MK-5108 
inhibitor (0.1 μM) induce autophagy in IMR-32 cells. Moreover, the combinatorial treatment of IMR-32 cells with the 14G2a 
mAb and CQ significantly potentiates cytotoxic effect, as compared to CQ used alone. Most importantly, we showed that 
interfering with autophagy at its early and late step augments the 14G2a mAb-induced apoptosis, therefore we can conclude 
that inhibition of autophagy is the primary mechanism of the CQ-mediated sensitization to the 14G2a mAb-induced apop-
tosis. Although, there was no virtual stimulation of autophagy in the 14G2a mAb-treated CHP-134 neuroblastoma cells, 
we were able to show that PHLDA1 protein positively regulates autophagy and this process exists in a mutually exclusive 
manner with apoptosis in PHLDA1-silenced CHP-134 cells.
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Abbreviations
FCS  Fetal calf serum
GD2  GD2 ganglioside
mAb  Monoclonal antibody
RT-qPCR  Reverse transcription and quantitative PCR
CQ  Chloroquine diphosphate salt
Baf  Bafilomycin A1
MK  MK-5108 inhibitor
Introduction
Neuroblastoma is the most common extracranial cancer in 
children [1]. High-risk neuroblastoma, documented to occur 
in half of all patients, is typically associated with metastasis 
to the liver, bone or bone marrow, and aggressive features 
such as MYCN oncogene amplification, as well as an unfa-
vorable prognosis [2]. Treatment of children > 18 months 
of age with widely disseminated neuroblastoma (stage 4) 
and those < 18 months with MYCN-amplified stage 4 disease 
remains one of the greatest challenges for pediatric oncolo-
gists [3]. The treatment methods used in the management 
of high-risk neuroblastoma include chemotherapy, surgery, 
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myeloablative therapy and stem cell transplant, radiotherapy, 
and use of agents such as ch14.18 in combination with IL-2/
GM-CSF and isotretinoin [3, 4]. Ch14.18 monoclonal anti-
bodies, being IgG1 human/mouse chimeric switch variant 
of murine 14G2a monoclonal antibody bind to GD2 gan-
glioside. GD2 is one of the most important molecular tar-
gets for immunotherapy in neuroblastoma. This is a surface 
glycolipid, highly expressed on neuroblastoma cells with 
only limited distribution on healthy tissues. Studies have 
shown that mAbs targeting GD2 inhibit tumor cell growth 
not only by means of immunological mechanisms such as 
antibody-dependent cell-mediated cytotoxicity and comple-
ment-dependent cytotoxicity, but also directly through cell 
death induction [5]. These features stress the potential for 
finding effective GD2-targeted therapies using monoclonal 
antibodies and their combinations with other agents for use 
in high-risk neuroblastoma patients. We have previously 
shown that the anti-GD2 14G2a mouse monoclonal antibody 
decreases survival of IMR-32 human neuroblastoma cells 
in a dose-dependent manner. Cell death evoked by this anti-
body exhibited several characteristics typical for apoptosis 
with partially caspase-dependent mechanism [6].
Another important target in neuroblastoma, which has 
gained wide popularity, is aurora A kinase. It is required 
for centrosome maturation and division, entry into mitosis 
and formation of the mitotic spindle [7]. The gene encod-
ing aurora A kinase is amplified in multiple human tumors 
such as breast, cervical or gastric tumors and neuroblastoma 
[7]. Overexpression of the AURKA gene in neuroblastoma 
is associated with high-risk, late-stage tumors, unfavorable 
histology, MYCN amplification, and in general decreased 
survival of neuroblastoma patients [8]. Therefore, aurora A 
kinase has been extensively studied as an antimitotic drug 
target. Several specific inhibitors have been developed and 
are currently evaluated in preclinical models as well as in 
different phases of clinical trials [9]. The effects of aurora 
A kinase inhibition are multiple, and include events such as 
abnormal spindle pole formation, cell-cycle arrest between 
phases G2-M and polyploidy, followed by induction of 
apoptosis [7]. Aurora A forms a complex with MYCN in 
MYCN-amplified neuroblastoma cells, protecting MYCN 
from proteasomal degradation during mitosis [10]. There-
fore, inhibition of aurora A kinase may be an effective strat-
egy to treat MYCN-amplified neuroblastoma. Our previous 
study showed that a small molecule, specific aurora A kinase 
inhibitor, MK-5108, decreases neuroblastoma cell survival, 
and when used in combination with the 14G2a mAb, signifi-
cantly potentiates cytotoxicity against neuroblastoma cells 
in vitro, as compared to MK-5108 used alone [11].
Recently evidence mounts on how another essential 
cellular process, autophagy, may be involved in the tumor 
biology. Autophagy is a homeostatic, catabolic degradation 
process responsible for cellular proteins and organelles being 
engulfed by autophagosomes, digested in lysosomes, and 
recycled to sustain cellular metabolism [12]. Autophagy was 
shown to have dual roles in cancer, acting both as a tumor 
suppressor by preventing the accumulation of damaged pro-
teins and organelles and as a mechanism of cell survival 
that can promote the growth of established tumors [13, 14]. 
Tumor cells induce autophagy in response to cellular stress 
and/or increased metabolic demands resulting from rapid 
cell proliferation. Autophagy-associated tolerance to stress 
enables cell survival by maintaining energy production that 
can lead to tumor growth and drug resistance [15]. As shown 
in preclinical models, inhibition of autophagy restored che-
mosensitivity and enhanced tumor cell death [16]. These 
results established autophagy as a therapeutic target and led 
to multiple clinical trials in humans to evaluate the effect of 
autophagy inhibition using hydroxychloroquine in combina-
tion with chemotherapy or targeted agents [17]. Contrary 
to the cytoprotective function of autophagy, which is sup-
ported by abundant evidence, prolonged stress and sustained 
autophagy may eventually lead to cell death when protein 
and organelle turnover overwhelm the capacity of the cell. 
In cancer cells, autophagy accompanied by nonapoptotic 
cell death has also been described [18, 19]. As autophagy 
is such a fundamental process, it is very important to estab-
lish how treatment strategy for neuroblastoma influences 
the functional status of autophagy. This is especially criti-
cal, as many current cancer therapeutics activate autophagy. 
Therefore, efforts to understand and modulate the autophagy 
pathway could provide new approaches to cancer therapy 
and prevention.
This study aimed at further elucidation of mechanisms 
governing cytotoxic activity of the anti-GD2 monoclonal 
antibody and the aurora A kinase specific inhibitor in the 
IMR-32 and CHP-134 human neuroblastoma cell lines, espe-
cially in the context of the possible stimulation of autophagy. 
Firstly, we showed that both agents induce autophagy in 
IMR-32 cells. Secondly, we studied the role of autophagy 
process in the 14G2a mAb-induced cell killing of IMR-32 
cells. We thoroughly characterized the crosstalk between 
intracellular processes such as autophagy and apoptosis 
modulated by the 14G2a mAb in IMR-32 cells. Finally, 
we explored a role of PHLDA1 protein in regulation of 
autophagy in CHP-134 neuroblastoma cells. We confirmed 
that PHLDA1 is able to positively regulate autophagy in the 
cell line.
Materials and methods
Cell culture
IMR-32 human neuroblastoma cell line was cultured in 
EMEM medium (M4655, Sigma-Aldrich) supplemented 
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with 10% fetal calf serum (10270106, Gibco), 1% non-
essential amino acid solution (M7145, Sigma-Aldrich), 
1 mM sodium pyruvate (S8636, Sigma-Aldrich) and 50 µg/
ml gentamicin (G1397, Sigma-Aldrich). CHP-134 cells were 
grown in RPMI 1640 medium (R8758, Sigma-Aldrich) sup-
plemented with 10% FCS and 50 µg/ml gentamicin. LAN-1 
cells were cultured in EMEM/F-12 (N6658, Sigma-Aldrich) 
medium diluted in 1:1 ratio, supplemented with 10% FCS, 
1% non-essential amino acid solution, 1 mM sodium pyru-
vate and 50 µg/ml gentamicin, while LAN-5 cells in RPMI 
1640 medium supplemented with 20% FCS and 50 µg/ml 
gentamicin. For preparation of positive controls, IMR-32 
and CHP-134 cells were cultured in amino acids-deprived 
Earle’s Balanced Salt (E2888, Sigma-Aldrich), supple-
mented with 10% FCS for 24 h. All cell lines were grown at 
37 °C in a 5%  CO2 atmosphere.
Antibody purification
Mouse GD2-binding mAbs, 14G2a (IgG2a) were puri-
fied from 14G2a hybridoma culture supernatants using the 
HiTrap Protein G HP column (17-0404-01, GE Healthcare 
Bio-Sciences AB) according to the manufacturer’s protocol. 
Antibodies were dialysed using D-Tube TM Dialyzer Midi 
tubes (71507-3, Millipore) against 4 liters of PBS (phos-
phate-buffered saline, pH 7.3–7.5) for 24 h at 4 °C. Protein 
concentration was measured using the BCA assay (B9643, 
C2284, Sigma-Aldrich) according to the manufacturer’s 
protocol.
Drugs treatment
IMR-32 and CHP-134 cells were pretreated with indicated 
concentration of chloroquine diphosphate salt (further 
abbreviated to CQ, C6628, Sigma-Aldrich) or bafilomycin 
A1 (further abbreviated to Baf, B1793, Sigma-Aldrich) for 
1.5 h at 37 °C and subsequently treated for a given time 
with either the 14G2a mAb at concentration of 40 μg/ml, or 
MK-5108 (further abbreviated to MK, S2770, Selleckchem) 
at concentration of 0.1 μM, seeded, and grown at 37 °C. 
Additionally, PBS-treated, water-treated or DMSO-treated 
control cells were included. Control cells were treated with 
equivalent volume of the solvent of the drug.
Cell viability tests
2 × 105 of IMR-32 cells/well and 5 × 103 of CHP-134 cells/
well were cultured on 96-well plates, and treated with 
given agents for 24, 48 or 72 h (with prior incubation with 
autophagy inhibitors). Cellular ATP content was measured 
using ATPlite Luminescence ATP Detection Assay System 
(6016947, PerkinElmer) according to manufacturer’s pro-
tocol using the Infinite M200 Reader (Tecan Group Ltd.).
Measurements of caspase 3/7 activity
For measurements of caspase 3/7 activity, 2 × 105 of IMR-
32 cells/well were cultured for 3 days in 100 μl of complete 
medium in a 96-well plate, after a given treatment. On the 
third day, cell cultures were analyzed using Caspase-Glo® 
3/7 Assay (G8090, Promega) according to the manufactur-
er’s protocol. Samples luminescent signals were analyzed in 
triplicate using the Infinite M200 Reader.
RNA isolation and RT‑qPCR
For RNA isolation, 1 × 106 of IMR-32 cells/well were 
grown in 5 ml of culture medium and 2.5 × 105 of CHP-134 
cells/well were grown in 5 ml of culture medium in 6-well 
plates. Total RNA was extracted using TRI-REAGENT® 
(TRI118, Lab Empire), as described in manufacturer’s pro-
tocol (Molecular Research Center, Inc.). 2 µg of total RNA 
was reverse-transcribed. Following the synthesis, cDNA was 
amplified in qPCR using the Eco Illumina (Illumina) system. 
For the normalization of each sample, ribosomal protein S13 
(RPS13) cDNA was used. Quantification was performed 
using the “ΔΔCt” relative quantitation method. All samples 
were run in triplicate. Primers used for qPCR reaction were 
designed using Primer-BLAST (http://www.ncbi.nlm.nih.
gov/tools /prime r-blast /), unless otherwise stated, and were 
as follows: LC3B (F: GAT GTC CGA CTT ATT CGA GAGC, 
R: TTG AGC TGT AAG CGC CTT CTA); ATG7 (F: ACC CAG 
AAG AAG CTG AAC GA, R: CTC ATT TGC TGC TTG TTC 
CA); BCN1 (F: AGG ATG ATG TCC ACA GAA AGTGC, R: 
AGT GAC CTT CAG TCT TCG GCTG); ATG12 (F: GCG AAC 
ACG AAC CAT CCA AG, R: CCA TCA CTG CCA AAA CAC 
TCAT); ATG5 (F: GGT GAA GGT GGT TCC TCC G, R: AGC 
CAA ACT TAG TAA GCA ACA GAC ), ATG16L (F: GCA TGA 
CGT ACC AAA CAG GC, R: ATC ACC AGT TGA GCT CCC 
CA), RPS13 (F: TCG GCT TTA CCC TAT CGA CGCAG, R: 
ACG TAC TTG TGC AAC ACC ATG TGA ) [20] and PHLDA1 
(F: TGC CTG AAA GGG GCA GCT CC, R: TGA TCT GGT 
GCG GGG CGG A) as described in [21].
Protein isolation and immunoblotting
For protein analysis, the IMR-32 (1 × 106) and CHP-134 
(0.25 × 106) cells/well were grown on 6-well plates. Whole 
cell extracts were obtained according to the TRI-REA-
GENT® manufacturer’s protocol. The protein lysates were 
resolved in the denaturing SDS-PAGE, and transferred onto 
a Immobilon®-P Transfer Membrane (IPVH00010, Milli-
pore). The membranes were treated with a blocking solu-
tion containing 10 mM Tris (pH 7.4), 150 mM NaCl, 0.05% 
Tween 20 and 5% nonfat dry milk for 1 h at room tempera-
ture, and incubated overnight with the respective primary 
antibody at 4 °C. After the washing steps, the membranes 
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were treated with the appropriate secondary antibody for 1 h 
at room temperature. The immunoreactive bands were visu-
alized using a chemiluminescence method (WBKLSO100, 
Immobilon Western HRP Substrate, Millipore) according 
to the manufacturer’s protocol. Chemiluminescence was 
detected with MicroChemi system (DNR Bio-Imaging). 
The intensity of the immunoreactive bands was determined 
by densitometric scanning to quantify changes in the pro-
tein levels and analyzed by Quantity One Analysis Software 
(BioRad). The values for analyzed protein among samples 
were normalized using the respective values for α-tubulin. 
The level of the protein expression in control samples was 
set as 1. The following monoclonal antibodies against: 
Beclin-1 (#3495); LC3A/B (#12741); ATG5 (#12994); 
ATG12 (#4180); ATG16L1 (#8089); ATG7 (#8558); ATG3 
(#3415); P62/SQSTM1 (#5114); α-tubulin (#2125); cleaved 
caspase-3 (#9664); cleaved PARP (#5625); PARP (#9542); 
Bcl-xl (#2764); Bax (#5023) and IgG, HRP-linked antibody 
(#7074) were purchased from Cell Signaling.
Fluorescent detection of autophagic compartments
IMR-32 (1 × 106) and CHP-134 (2.5 × 105) cells/well were 
pretreated with CQ and subsequently treated with respective 
drugs (14G2a mAb, MK-5108 or their respective controls), 
seeded at 6-well plate and after given time prepared for 
detection of autophagic compartments with the CYTO-ID 
dye according to the manufacturer’s protocol (ENZ-51031, 
CYTO-ID® Autophagy Detection Kit, ENZO). Briefly, 
cells were collected to 1.5 ml tubes after the treatment and 
washed with 1× Assay Buffer. Next, cells were stained 
with the CYTO-ID dye for detection of autophagic com-
partments and counterstained with Hoechst 33342 Nuclear 
Stain for 30 min at 37 °C in the dark. After staining, cells 
were washed two times and used for measurements using a 
fluorescence microplate reader (1:1000 dilution of each dye 
in 1× Assay Buffer) and for florescence microscopy applica-
tion (1:2000 dilution of CYTO-ID® and 1:1000 dilution of 
Hoechst 33342 in 1× Assay Buffer). For microplate reader 
measurements, cells were re-suspended in 1× Assay Buffer, 
seeded on a 96-well black plate in triplicate (2.5 × 105 cells 
per 100 μl) and the signals were analyzed with a fluores-
cence microplate reader (CLARIOstar®, BMG LABTECH). 
Relative mean fluorescence intensity of CYTO-ID was 
monitored at 24, 48 and 72 h and divided by relative ATP 
level of the respective groups of cells (to normalize signals 
to number of viable cells). For fluorescence microscopy 
application, cells were fixed in 4% paraformaldehyde for 
20 min, washed three times and drops of cell suspensions 
were applied onto glass microscope slides, overlaid with 
coverslips, and visualized under the fluorescent microscope 
(Carl Zeiss Microscopy, LLC). The standard FITC (excita-
tion ~ 480 nm, emission ~ 530 nm) and DAPI (excitation 
~ 340 nm, emission ~ 480 nm) filters were set for imaging the 
autophagic and nuclear signals. Relative mean fluorescence 
intensity of CYTO-ID-stained autophagic compartments 
was quantified in five randomly selected photomicrographs 
(taken using a 40× objective). ImageJ 1.50i software (Wayne 
Rasband, National Institutes of Health, USA) was used for 
quantification of the dyes fluorescence.
Electron microscopy
IMR-32 (1 × 106) and CHP-134 (2.5 × 105) cells/well were 
pretreated with CQ and subsequently treated with the 14G2a 
mAb or PBS and seeded at a 6-well plate. After 48 h cells 
were prepared for detection of autophagic compartments 
by transmission electron microscopy (TEM). IMR-32 and 
CHP-134 cells were fixed with 2.5% glutaraldehyde in 0.1 M 
cacodylic buffer, washed with 0.1 M cacodylic buffer, fol-
lowed by 1%  OsO4 (1 h). After dehydration in graded etha-
nol (50% 1 × 10 min, 70% 1 × 10 min, 96% 1 × 10 min, 100% 
2×/15 min) and propylene oxide 2 × 10 min, samples were 
gradually infiltrated with resin Poly/Bed812 mixed with pro-
pylene oxide—2:1 (2 h) and 1:1 (overnight). Next, samples 
in fresh resin were put to oven for polymerization at 60 °C 
for 3 days. The samples were cut using Microtome (Leica). 
The thin sections (approximately 70 nm) on one slot with 
formvar covered by carbon were stained with uranyl acetate 
and lead citrate for observation using JEOL 2100HT TEM 
(JEOL). The percentage of residual bodies scattered along 
cytoplasm on a cell cross-section was measured by placing 
a net (20 pxl × 20 pxl) on the image (2048 pxl × 2048 pxl). 
The net was generated in Photo Filtre 7 software, where the 
number of squares per the area of residual bodies (x) and the 
cell (y) was counted. The percentage of residual bodies was 
calculated as ∑x/∑y × 100%. The mean from ten images 
was taken for calculations.
siRNA transfection
1.5 × 106 of IMR-32 cells/well were seeded in 2.5 ml of 
complete medium on 6-well plates, 24 h prior to siRNA 
transfection. On the day of transfection, Silencer® Select 
siRNAs sequences (Ambion) either for ATG7 silencing 
(#4392420) or control (Mock) siRNAs (#4390843) were 
added to Opti-MEM medium (319850-047, Gibco). A Lipo-
fectamine® RNAiMAX Reagent (#13778030, Ambion) was 
used according to the manufacturer’s recommendations, with 
diluted Lipofectamine® RNAiMAX Reagent: diluted siR-
NAs ratio of 1:1 in Opti-MEM medium. 250 μl of the trans-
fection mix was added to 2.5 ml of complete fresh medium 
at the final siRNAs concentration of 10 nM. One well con-
tained cells that were not transfected (WT). For the purpose 
of study relying on early interference with autophagy, 24 h 
after transfection with ATG7-targeting siRNAs or control 
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siRNAs, cells were treated with combination of the 14G2a 
mAb and/or CQ for the next 24 h. 24 and 48 h after transfec-
tion (depending on the described type of treatment) ATP and 
caspase 3/7 activity was measured and cells were collected 
for subsequent RNA and protein isolation.
shRNA leniviral particles transduction
CHP-134 cells (5 × 104) were plated in 2 ml of complete 
medium in a 12-well plate, 24 h prior to viral infection. 
On the day of infection media were replaced with 2 ml of 
complete medium with Polybrene® (sc-134220, Santa Cruz 
Biotechnology) at the final concentration of 5 µg/ml. For 
the PHLDA1 gene silencing, cells were infected by adding 
40 µl of the shRNA Lentiviral Particles stock (sc-36631-V, 
Santa Cruz Biotechnology) to the culture. Additionally, one 
well with cells was transduced with Control shRNA Lenti-
viral Particles (sc-108080, Santa Cruz Biotechnology) and 
one well with cells was transduced with copGFP Control 
Lentiviral Particles (sc-108084, Santa Cruz Biotechnol-
ogy) for measuring efficiency of transduction. Finally, one 
well contained cells that were not transduced (WT). On the 
third day media were replaced with 2 ml of fresh complete 
medium without Polybrene. On the fourth day, puromycin 
dihydrochloride (sc-108071, Santa Cruz Biotechnology) 
was added to PHLDA1-silenced and control (Mock) cells to 
the fresh media at the concentration of 5 µg/ml. To derive 
PHLDA1-stably silenced clones, media were replaced with 
fresh medium containing puromycin every 3–4 days, until 
resistant colonies were selected. Then, these colonies were 
transferred with small pipette tips to new culture plates and 
expanded. The effects of PHLDA1-silencing were assessed 
by RT-qPCR and confirmed by western blot analyses.
Statistical analyses
Data was presented as means ± SEM. All experiments were 
repeated at least three times and series of pairwise tests (t 
test) were performed, comparing means of treated cells ver-
sus control cells, set as 1 (black baseline). For  IC50 calcula-
tions, curves were fitted using dose response model with the 
OriginPro9.1 software.
Results
Analysis of autophagy‑related genes and proteins 
in the 14G2a mAb‑treated IMR‑32 and CHP‑134 cells
We assessed expression level of autophagy-associated 
genes e.g., LC3B (encoding for LC3B), BCN-1 (encoding 
for Beclin-1) and genes from the ATG family (autophagy-
related genes) using RT-qPCR (Fig. 1a). We observed the 
significant increase in the expression of LC3B and BCN-1 
genes in the 14G2a mAb-treated IMR-32 cells (at concen-
tration of 40 μg/ml) to approximately 1.4 and non-signifi-
cant up-regulation of ATG12 and ATG5 genes expression, 
as compared to the control cells. Significant increase in the 
mRNA expression level of ATG16L to 1.5 was also noted, 
as compared to control, but no change in mRNA expres-
sion was visible for ATG7. Although, autophagy genes 
may be transcriptionally upregulated in response to stress 
conditions that induce autophagy, there is no clear evi-
dence that autophagic activity per se is related to transcrip-
tionally upregulated genes [22]. Moreover, the expression 
of microtubule-associated protein light chain 3 (MAP-
LC3A/B, abbreviated further to LC3A/B), was also meas-
ured as a key autophagy marker. LC3A/B is incorporated 
into the autophagosome membrane and it can be tracked 
until fusion with the lysosome vesicle [23]. The LC3A/B 
exists in two forms: the cytoplasmic LC3A/B-I (16 kDa) 
and the autophagosome-associated, undergoing proteolytic 
cleavage and modification, LC3A/B-II (14 kDa) form [24]. 
Indeed, in IMR-32 cells we observed significantly higher 
level of LC3A/B-II converted form at 48 h, as compared 
to the control cells as assessed by western blot (Fig. 1b, 
c). The amount of LC3A/B-II usually correlates well with 
the number of autophagosomes, therefore the increase of 
LC3A/B-II expression signal to 1.5 indicates accumula-
tion of autophagosomes in the 14G2a mAb-treated IMR-32 
cells. Furthermore, we tracked changes in expression of 
other proteins related to autophagy pathway i.e., Beclin-1, 
ATG3, ATG7, ATG12, ATG16L, and ATG5 in the 14G2a 
mAb-treated and the control IMR-32 cells. We observed a 
significant up-regulation of ATG16L expression signal to 
1.4, slight non-significant increase in ATG5 level and mar-
ginal changes in regulation of the other proteins (Fig. 1b, 
c). However, ATG proteins are constitutively expressed in 
sufficient amounts, and their posttranslational modifica-
tions and/or associations with members of the autophagic 
machinery, rather than regulation of their expression lev-
els, is critical for their activity in the autophagy pathway 
[22]. These results allowed us to show that the 14G2a 
mAb modulates expression of some autophagy-associated 
molecules in IMR-32 cells on mRNA and protein levels. 
CHP-134, another neuroblastoma cell line responsive 
to the 14G2a mAb treatment, was also characterized in 
terms of regulation of autophagy-associated genes and 
proteins. However, no significant changes or only a slight 
decrease in the aforementioned genes mRNA expression 
and proteins levels were observed in the 14G2 mAb-
treated cells, as compared to the control cells (Supple-
mentary Fig. 1a–c). These results suggest no enhancement 
of autophagy process in the 14G2a mAb-treated CHP-134 
cell cultures. Nevertheless, autophagy-related molecules 
regulated in the 14G2a mAb-treated cells should not be 
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considered as the only indicators for monitoring autophagy 
and these results are further supported by other types of 
analyses.
Monitoring autophagic flux in the IMR‑32 
and CHP‑134 cells
The accumulation of autophagosomes may represent either 
the increased generation of autophagosomes and/or a block 
in autophagosomal maturation and the completion of the 
autophagy pathway [22, 25]. To distinguish between these 
two scenarios, we performed LC3A/B turnover assay to 
verify whether autophagosome accumulation is due to 
autophagy induction or rather a block in downstream steps. 
The LC3A/B turnover assay is one of the principal methods 
to measure “autophagic flux” i.e., the amount of LC3A/B that 
is delivered to lysosomes for degradation [26]. To this end, 
cells were treated with lysosomotropic reagent—chloroquine 
Fig. 1  Analysis of autophagy in 
the 14G2a mAb-treated IMR-32 
neuroblastoma cells. a Relative 
gene expression of LC3B, BCN-
1, ATG7, ATG12, ATG16L, 
and ATG5 in the 14G2a 
mAb-treated IMR-32 cells (in 
concentration of 40 μg/ml), as 
compared to the control (PBS-
treated cells), assessed at 48 h 
by RT-qPCR. RPS13 cDNA was 
used as the reference. b Relative 
protein expression of Beclin-1, 
ATG3, LC3A/B-I, LC3A/B-II, 
ATG7, ATG12, ATG16L, and 
ATG5 was measured in IMR-32 
cells at 48 h by western blot 
and normalized to α-tubulin. 
Expression of proteins and their 
respective genes in the control 
cells equals 1 (black baseline). 
c Representative immunoblots 
are presented. (D) Relative 
LC3A/B-I expression affected 
by the 14G2a or/and CQ 
treatment in IMR-32 cells as 
assessed by western blot. Cells 
were pre-treated with 10 μM 
CQ for 1.5 h and subsequently 
treated with the 14G2a mAb 
or PBS (control) for 48 and 
72 h. e LC3A/B-II—estimated 
autophagy flux affected by 
the 14G2a mAb or/and CQ 
treatment in IMR-32 cells as 
assessed by western blot. f 
Relative P62 expression affected 
by the 14G2a mAb or/and CQ 
treatment in IMR-32 cells as 
assessed by western blot. g, h 
Representative immunoblots 
are presented. C—control, 
PBS-treated cells; 14G2a—the 
14G2a mAb-treated cells; 
CQ—chloroquine-treated cells. 
P-values for t test were as fol-
low: *p < 0.05, ***p < 0.001
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diphosphate salt (abbreviated further to CQ), a weak base 
amine that accumulates in the lysosomal lumen and inhibits 
the fusion of autophagosomes with lysosomes. Accordingly, 
the differences in the amount of LC3A/B-II between sam-
ples in the presence and absence of CQ represent changes 
in autophagic flux. If cells are treated with CQ, degradation 
of LC3A/B-II is partially inhibited, and LC3A/B-II accumu-
lates. The levels of LC3A/B-I (Fig. 1d, g, h) and LC3A/B-II 
(Fig. 1e, g, h) forms in IMR-32 cells were analyzed by west-
ern blot. We showed that autophagic flux occurs in IMR-32 
cells treated with the 14G2a mAb because the signal of the 
level of LC3A/B-II is increased to respectively 1.7 and 1.6 
at 48 and 72 h, as compared to the control cells (Fig. 1e, g, 
h). Treatment with the 14G2a mAb and CQ further increases 
LC3A/B-II level signals to 12.3 and 13.1, respectively, pro-
viding that autophagic flux is affected, manifesting itself by 
further LC3A/B-II accumulation. This allowed us to con-
firm an actual induction of autophagy in IMR-32 cells via 
autophagosomes accumulation, but not via autophagosomes 
degradation. On contrary, the signal for the LC3A/B-I form 
increased only to a small extent (to 2.5) for the 14G2a mAb 
and CQ used (Fig. 1d, g, h), as compared to LC3A/B-II 
signal, which escalated for the combined treatment. This 
indicates that pool of the cytoplasmic LC3A/B-I form is 
intensely converted to the autophagosome-bound LC3A/B-
II protein. Expression level of another important autophagy 
marker, P62 (SQSTM1) protein, was also monitored in time 
(Fig. 1f–h). Level of this protein is inversely correlated with 
induction of autophagy, as the P62 protein itself is a sub-
ject of degradation in the autolysosome [27]. Therefore, the 
observed decrease in the P62 signal level to 0.7 in the 14G2a 
mAb-treated cells, as compared to the control cells and a 
consecutive decrease of the P62 protein signal to 2.1 in the 
14G2a mAb/CQ-treated cells, as compared to CQ-treated 
cells (2.5), confirm autophagy induction in our model at 48 h 
(Fig. 1f–h). An overall estimation of autophagy by perform-
ing the autophagic flux assay in CHP-134 cells upon the 
14G2a mAb treatment showed no elevated autophagic activ-
ity in the 14G2a mAb-treated CHP-134 cells, as compared 
to control (Supplementary Fig. 1d–h).
Detection of autophagic compartments 
with the CYTO‑ID dye in the IMR‑32 and CHP‑134 
cells
We also measured fluorescence of the CYTO-ID dye to 
estimate autophagic flux in IMR-32 cells treated with the 
14G2a mAb and/or CQ (Fig. 2a). Application of this dye 
was reported to be effective in labeling autophagic compart-
ments with minimal staining of lysosomes [28]. The 14G2a 
mAb treatment shows the induction of CYTO-ID-estimated 
autophagic flux in IMR-32 cells to approximately 1.3, meas-
ured as relative fluorescence intensity. While the 14G2a 
mAb and CQ combined treatment indicates that autophagic 
flux is affected in IMR-32 cells as the fluorescence intensity 
of CYTO-ID is significantly increased when treated with 
both agents (in range of 2.2–3.3 depending on incubation 
time), as compared to single agent-treated IMR-32 cells 
and to control. To further explore the ability of the 14G2a 
mAb to induce autophagy in IMR-32 cells, the autophagic 
compartments, a highly characteristic feature of autophagic 
cells, cells were stained with CYTO-ID dye and visualized 
by fluorescent microscopy. We observed only a slight non-
significant increase in the CYTO-ID dye fluorescence signal 
in the 14G2a mAb treated cells to 1.2, as compared to the 
control cells (Fig. 2b). However, we demonstrated that the 
fluorescence signal of autophagic compartments was by far 
the greatest for the combination of the 14G2a mAb and CQ, 
as compared to the control cells. It was elevated to 2.0 for the 
combination treatment and exceeded the fluorescence signal 
observed for CQ-treated cells (1.8), providing that induction 
of autophagy is present in these cells. Autophagic compart-
ments appeared as green fluorescent cytoplasmic vesicles, 
while nuclei were blue-stained with the Hoechst 33342 dye 
(Fig. 2c). The observed accumulation of autophagic com-
partments is one of the hallmark of autophagic response. On 
the contrary, monitoring of relative fluorescence intensity of 
CYTO-ID in time in CHP-134 cells by a microplate reader 
(Supplementary Fig. 2a) and detection of CYTO-ID fluo-
rescence signal by fluorescence microscopy (Supplemen-
tary Fig. 2b, c) showed no advanced autophagy in the 14G2 
mAb-treated cells, as compared to control cells.
Monitoring of autophagosomes formation 
by electron microscopy in the 14G2a mAb‑treated 
IMR‑32 and CHP‑134 cells
Identification of autophagosomes/autolysosomes and moni-
toring of their number were done by TEM in the control, the 
14G2a mAb-treated and the 14G2a and/or CQ-treated neuro-
blastoma IMR-32 and CHP-134 cells. At the ultrastructural 
level, an autophagosome is defined as a double-membraned 
structure containing undigested cytoplasmic contents, which 
has not yet fused with a lysosome. While, the autolyso-
some is a hybrid organelle generated by the fusion of an 
autophagosome and a lysosome, which has a single limiting 
membrane and contains cytoplasmic materials at various 
stages of degradation [29]. In the 14G2a mAb-treated IMR-
32 cells, we observed a wide spectrum of cellular structures 
including autophagosomes that contain undigested cellular 
components, vesicles containing electron-dense undigested 
material or containing partially degraded granular cyto-
plasm indicative of autophagic activity (Fig. 3). Number of 
autophagosomes that appears in cytoplasm was juxtaposed 
in groups of the 14G2a mAb-treated and the control IMR-
32 cells. We observed numerous and relatively few such 
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structures in the respective groups of cells. Moreover, ultra-
structural cell morphology shows the typical hallmarks of 
autophagy, especially in the 14G2a mAb-treated cells. There 
is no nuclear chromatin condensation and endoplasmic retic-
ulum is swollen. Interestingly, after treatment with the CQ, a 
great number of residual bodies (telolysosomes) that contain 
material not digested by lysosomal enzymes, can be visual-
ized in the cytoplasm of the IMR-32 cells. The percentage 
of these structures on average accounted for 5.1% of a cell 
cross-section. These structures were even more abundant in 
the 14G2a mAb and CQ-treated cells, where the percentage 
of these structures on average accounted for 10.4% of a cell 
cross-section. This, once again, corresponds to autophagy 
process being inhibited via CQ in the 14G2a mAb-treated 
IMR-32 cells. In CHP-134 cells, accumulation of insoluble, 
electron-dense aggregates, perhaps too large to be engulfed 
by autophagosomes or not recognized as material to be tar-
geted for autophagic degradation, was also shown in the 
14G2a mAb/CQ-treated cells, however to a lesser extent 
(Supplementary Fig. 3).
Elucidation of autophagy role in the 14G2 
mAb‑induced cell death of IMR‑32 cells
Our studies showed that the 14G2a mAb induces autophagy 
in IMR-32 neuroblastoma cells. Therefore, we wanted to 
determine the significance of autophagy in the 14G2a mAb-
mediated cytotoxicity in IMR-32 cells. Autophagy process 
C
C                                                              14G2a   
CQ                                                         14G2a+CQ                                                       PC
BA
Fig. 2  Relevance of autophagy flux in the 14G2a-treated IMR-
32 cells. Cells were pre-treated with 10  μM CQ for 1.5  h and sub-
sequently treated with the 14G2a mAb or PBS (control). a CYTO-
ID—estimated autophagy flux in IMR-32. Relative mean fluorescence 
intensity of the CYTO-ID dye was measured at 24, 48, and 72 h by 
a microplate reader and divided by ATP level signals of the respec-
tive groups of cells. b IMR-32 cells were stained with CYTO-ID and 
Hoechst 33342, fixed and visualized under the fluorescence micro-
scope. Relative mean fluorescence intensity of CYTO-ID-stained 
autophagic compartments was quantified in five randomly selected 
photomicrographs (taken using a ×40 objective). c Localization of 
CYTO-ID and Hoechst 33342 fluorescence dyes in IMR-32 cells was 
assessed using fluorescence microscope at 48  h. Scale bar 25  μm. 
C—control, PBS-treated cells; 14G2a—the 14G2a mAb-treated cells; 
CQ—chloroquine-treated cells; PC—positive control, cells grown in 
amino acids-free medium for 24 h. P-values for t test were as follow: 
*p < 0.05
500 Apoptosis (2018) 23:492–511
1 3
may act as a double edged sword by being either pro- or 
anti-tumor, depending upon a tumor type or a drug used. In 
order to define the role of the autophagy in the 14G2a mAb-
cell killing, we asked whether disruption of the autophagic 
flux sensitizes IMR-32 neuroblastoma cells to the 14G2a 
mAb-induced cytotoxicity. To this end, we used the lys-
osomotropic agent—CQ, which inhibits autophagosome-
lysosome fusion. We studied if CQ acts in concert with the 
14G2a mAb to cause greater loss in cellular ATP level in 
IMR-32 neuroblastoma cells. Inhibition of autophagy by 
indicated concentrations of CQ (1.25–80 μM) potentiated 
cytotoxic effect of the 14G2a mAb, as compared to CQ 
used alone, as assessed by measuring cellular ATP content 
(Supplementary Fig. 4a). However, only for the range of 
CQ concentration (10–80 μM) used in combination with 
the 14G2a mAb, a visible decrease in the ATP level was 
observed, as compared to the 14G2a mAb used alone. Such 
an effect was not observed for lower concentration of CQ 
(1.25–5 μM) used in combination with the 14G2a mAb. In 
the presence of the 14G2a mAb and CQ, the IC50 value was 
18.92 ± 0.99, which was lower than the IC50 value for CQ 
alone (22.62 ± 0.76). Similarly, simultaneous combination 
of the 14G2a mAb treatment and inhibition of autophagy by 
bafilomycin A1 (a specific inhibitor of the lysosomal pro-
ton pump, which inhibits autophagolysosome formation, 
abbreviated further to Baf), causes advanced cytotoxicity 
as compared to monotherapy with the Baf (Supplementary 
Fig. 4b). For the double-agent regimen, the IC50 value was 
24.72 ± 5.02, which was higher than the IC50 value for Baf 
alone (20.07 ± 2.06). Most importantly, disruption of the 
autophagic flux by CQ sensitizes neuroblastoma cells to the 
14G2a mAb-induced apoptosis, as assessed by an increase 
of cleaved-caspase 3, cleaved PARP, and pro-apoptotic 
Bax protein level signals to 7.5, 3.7 and 2.0, respectively 
(Fig. 4a, b). Apoptosis analyzed by measuring activity of 
caspase 3/7 is also significantly increased to 5.7 in IMR-
32 cells treated with combination of the 14G2a mAb and 
CQ, as compared to both agents used alone and the control 
cells (Fig. 4c). Our previous studies showed that treatment 
with the 14G2a mAb downregulates the PI3K/AKT/mTOR 
pathway [30], and in this study we postulate that the 14G2a 
mAb triggers autophagy in IMR-32 cells. Since autophagy 
has been described as an adaptive stress response that pro-
motes cell survival upon PI3K/mTOR inhibition [31], we 
further investigated the functional relevance of autophagy 
in the 14G2a mAb/CQ-mediated apoptosis in IMR-32 cells. 
To this end, we used two approaches to block autophagy. 
In the first approach, we inhibited autophagy at the early 
phase by siRNAs-mediated silencing of ATG7 in IMR-32 
cells. IMR-32 cells were transfected with ATG7 siRNAs or 
control (Mock) siRNAs, and the ATG7 gene mRNA as well 
as ATG7 protein expression were analyzed, as compared 
to the non-transfected (WT) cells. The ATG7 gene mRNA 
expression and protein levels were significantly reduced at 
24 h after transfection to 0.5 and 0.6, respectively (Fig. 4d). 
Furthermore, IMR-32 cells were treated 24 h after trans-
fection with the 14G2a mAb (40 μg/ml) or PBS (control) 
for the next 24 h and LC3A/B expression was analyzed by 
Fig. 3  Assessment of autophagy 
features of the 14G2a-treated 
IMR-32 cells by TEM. IMR-
32 cells were pre-treated 
with 10 μM CQ for 1.5 h and 
subsequently treated with the 
14G2a mAb or PBS for 48 h, 
and visualized by TEM. The 
representative images account 
for exemplary photos of cells 
selected from at least 20 other 
photos of cells visualized under 
the microscope for each type 
of treatment. Autophagosomes 
(arrows) and residual bodies 
(arrowheads) are scattered along 
a cytoplasm. Scale bar 2 μm. 
N—nucleus, M—mitochondria. 
C—control, PBS-treated cells; 
14G2a—the 14G2a mAb-
treated cells; CQ—chloroquine-
treated cells
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M
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Fig. 4  Effects of interfering with the 14G2a mAb-stimulated 
autophagy on the 14G2a/CQ-induced apoptosis. a Cells were pre-
treated with 10  μM CQ for 1.5  h and subsequently treated with 
the 14G2a mAb or PBS (control) for 72  h. Relative autophagy and 
apoptosis-associated protein expression levels (P62, Bcl-xl, cleaved 
caspase 3, cleaved PARP, LC3A/B-I, LC3A/B-II, ATG7, ATG3, 
and Bax) were measured in control and the 14G2a mAb and/or CQ 
treated IMR-32 cells by western blot and normalized to α-tubulin. b 
Representative blots are presented. c Relative caspase 3/7 level was 
measured in control and 14G2a mAb and/or CQ-treated IMR-32 
cells and was divided by ATP level signals of the respective groups 
of cells. d IMR-32 cells were transfected with ATG7 siRNA (S) or 
control siRNA (Mock). The ATG7 gene mRNA and ATG7 protein 
expression levels were analyzed at 24  h by RT-qPCR and western 
blot, respectively and compared to non-transfected cells (WT). RPS13 
cDNA and α-tubulin protein were used respectively, as the references. 
e IMR-32 cells were treated 24 h after siRNA transfection with the 
14G2a mAb (40 μg/ml) or PBS (control) for 24 h. LC3A/B expres-
sion was analyzed by western blot, α-tubulin served as the load-
ing control. f Relative expression levels of cleaved caspase 3 and g 
cleaved PARP were measured at 24 h after transfection in the 14G2a 
mAb, and/or CQ-treated ATG7 silenced (S), the control cells (Mock). 
h Representative blots are presented. i LC3A/B expression was deter-
mined by western blot in IMR-32 cells treated with 10  μM CQ or 
16 nM Baf for 24 h. j The relative caspase 3/7 level was measured in 
IMR-32 cells treated with 14G2a mAb (40 μg/ml), and/or indicated 
concentrations of Baf or its solvent—DMSO, and divided by ATP 
level signals of the respective groups of cells. C—control, solvent-
treated cells (PBS for the 14G2a mAb, water for CQ or DMSO for 
Baf); 14G2a—the 14G2a mAb-treated cells; CQ—chloroquine-
treated cells; Baf—bafilomycin-treated cells. P-values for t test were 
as follow: *p < 0.05, **p < 0.01
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western blot. The experiments showed that knockdown of 
ATG7 resulted in decreased conversion of LC3A/B-I into 
LC3A/B-II form both in control and the 14G2a mAb-treated 
cells, demonstrating that ATG7 silencing reduced basal and 
the 14G2a mAb-stimulated autophagy (Fig. 4e). The effect 
of ATG7 silencing on apoptosis was concluded upon assess-
ing cleaved caspase 3 and cleaved PARP levels. Measuring 
levels of cleaved caspase 3 and cleaved PARP and compar-
ing it to the control (Mock) cells demonstrated no induction 
of apoptotic features in control and CQ-treated IMR-32 cells 
(Fig. 4f–h). However, for the 14G2a mAb-treated IMR-32 
cells, we showed increase in cleaved caspase 3 and cleaved 
PARP in ATG7-silenced cells, as compared to Mock cells, 
indicating that this treatment rendered IMR-32 cells more 
prone to apoptotic death. Therefore, we can conclude that 
ATG7 knockdown with siRNA increased the induction of 
apoptosis by monotherapy with the 14G2a mAb and to a 
smaller extent by combination treatment with the 14G2a 
mAb plus CQ. These results of treatment with the 14G2a 
mAb in conditions of ATG7 silencing prove that inhibition 
of autophagy at the early stage acts in favor of the 14G2a 
mAb-induced apoptosis. The 14G2a mAb and CQ treatment 
as well as knockdown of ATG7 showed greater effects on 
inducing apoptotic features, indicating that interfering with 
autophagy at an early step supports the 14G2a mAb-induced 
apoptosis. In the second approach we interfered with the 
late phase of autophagy using Baf. Baf was also similarly 
potent as compared to CQ to interrupt the autophagic flux 
as indicated by the accumulation of LC3A/B-II (Fig. 4i). 
Combined treatment with the 14G2a mAb (40 μg/ml) and 
Baf (at the final concentration of 16 nM) showed by far the 
greatest induction of apoptosis, that increased about three-
fold, as compared to monotherapy with the 14G2a mAb and 
about sixfold as compared to Baf used alone, analyzed by 
measuring caspase 3/7 activities (Fig. 4j). This set of results 
indicates that interfering with autophagy at a late step also 
augments the 14G2a mAb-induced apoptosis. Finally, we 
could conclude that inhibition of autophagy at both the early 
and the late stage is the primary mechanism of the CQ-medi-
ated sensitization to the 14G2a-induced apoptosis.
Assessing relevance of autophagy in non‑apoptotic 
setting in CHP‑134, LA‑N‑1 and LA‑N‑5 cells
Another interesting aspect which was explored, was signifi-
cance of autophagy in neuroblastoma cell lines which have 
shown no apoptotic characteristics upon the 14G2a mAb 
treatment. We have previously shown that the 14G2a mAb 
causes cell death with partial characteristics of apoptosis in 
IMR-32 cells and no evident features of apoptosis in CHP-
134, LA-N-1 and LA-N-5 cells, indicating disparate mecha-
nisms of the 14G2a mAb-induced cell killing in different 
cell lines [11]. Our results showed also that the 14G2a mAb 
does not induce autophagy in CHP-134 beyond basal level. 
Firstly, we aimed to clarify how inhibition of autophagy at a 
constitutive level may influence cytotoxic effect exerted by 
the 14G2a mAb on CHP-134, LA-N-1 and LA-N-5 cells, in 
which apparent apoptotic features were not stated. There-
fore, we asked if the inhibition of autophagy by CQ and 
Baf inhibitors, enhances the 14G2a mAb-induced cytotox-
icity. Combined treatment with the 14G2a mAb (40 μg/ml) 
and indicated concentrations of CQ (2.5–10 μM) proved to 
have no greater effect on cellular ATP level, as compared 
to the 14G2a mAb used alone in CHP-134 (Supplementary 
Fig. 4c), LA-N-1 cells (Supplementary Fig. 4e) and LA-N-5 
(Supplementary Fig. 4g). Neither simultaneous treatment 
with the 14G2a mAb and inhibition of autophagolyso-
some formation by Baf in a range of tested concentrations 
(2–8 nM) resulted in enhanced tumor cells-killing, as com-
pared to the 14G2a mAb treatment alone, as determined by 
measuring cellular ATP content in CHP-134 (Supplemen-
tary Fig. 4d), LA-N-1 (Supplementary Fig. 4f) and LA-N-5 
(Supplementary Fig. 4h). Only for 20 μM concentration 
of CQ used in combination with the 14G2a mAb, visible 
decrease in ATP level was observed in all neuroblastoma 
line tested, as compared to the 14G2a mAb used alone. How-
ever, in CHP-134 and LA-N-5 cells, treated with the 14G2a 
mAb and CQ, reduction of ATP level was measured, as com-
pared to monotherapy with CQ, showing greater potential of 
autophagy inhibition for the optimal 14G2a mAb-induced 
tumor cells-killing. Similar effects in potentiating cytotoxic-
ity against tested neuroblastoma cells were also noted for the 
14G2a mAb and Baf-combined treatment, as compared to 
Baf-treated cells (used in concentration of 16 μM) in CHP-
134 cells and LA-N-5.
Characterization of the PHLDA1 protein role 
in regulation of autophagy and apoptosis 
in CHP‑134 cells upon the 14G2a mAb treatment
PHLDA1/TDAG51 (pleckstrin homology-like domain fam-
ily A member 1/T cell death-associated gene 51) was first 
identified in murine T lymphocytes where it is required for 
activation of induced cell death [32]. The gene encodes a 
401-amino acid protein that contains a central pleckstrin 
homology domain common to proteins involved in intracel-
lular signaling, or found in constituents of the cytoskeleton. 
The protein is ubiquitously expressed in a wide range of 
normal and cancer tissues. Its function depends on cell type 
and cellular environment, becoming either proapoptotic or 
prosurvival [33]. PHLDA1 expression is induced by a vari-
ety of external stimuli, and there is evidence showing that 
it might act as a mediator of both autophagy and apoptosis, 
although the exact biochemical and biological function of 
PHLDA1 is still unclear. The PHLDA1 gene was found to 
be up-regulated in both autophagy and apoptosis processes 
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induced by rapamycin and silencing of this gene resulted in 
a reduction of these activities in T-47D breast carcinoma 
cells [34]. This observation clearly indicates that PHLDA1 
positively regulates both apoptosis and autophagy pathways.
We have previously implicated that the PHLDA1 protein 
level is significantly increased after the 14G2a mAb treat-
ment, as compared to the control IMR-32 cells [11]. In addi-
tion, we have previously shown that silencing of the PHLDA1 
gene results in induction of autophagic activity and inhibits 
apoptotic characteristics in IMR-32 cells when treated with 
the 14G2a mAb, thus contributing to apoptosis resistance 
[21]. To explain the observed difference between IMR-32 and 
CHP-134 in autophagy regulation, with no autophagy stimula-
tion upon the 14G2a mAb treatment in the latter, we further 
elaborated on the potential role of PHLDA1 in autophagy 
modulation in the CHP-134 cell line. Our results along with 
findings of other groups prompted us to investigate the pos-
sible role of PHLDA1 as an autophagy modulator in neuro-
blastoma cells. To address a question if PHLDA1 positively 
modulates autophagy, we derived CHP-134 cells with sta-
bly silenced expression of the PHLDA1 gene by a lentivirus 
vector-based RNAi approach. The expression of PHLDA1 
gene in four selected PHLDA1-silenced clones (S5, S6, S16, 
S17) ranged from 0.3 to 0.5, as assessed by qPCR, in com-
parison to control (Mock) and non-transduced (WT) cells, for 
which expression level equaled 1 (Fig. 5a). Consequently, the 
expression of the PHLDA1 protein was reduced in all four 
selected clones with signals ranging from 0.3 to 0.7 of WT, 
as assessed by western blot (Fig. 5b). Next, the expression of 
autophagy-associated proteins was screened in these clones 
(Supplementary Fig. 5a). We observed that LC3A/B-II level 
was markedly decreased in all four PHLDA1-silenced clones, 
which was accompanied by an evident increase in the P62 
level, as compared to WT cells. This inverse correlation cor-
responds to autophagy process being inhibited upon silencing 
of the PHLDA1 gene. Moreover, an increase in apoptosis-
associated proteins i.e., cleaved caspase 3 and cleaved PARP 
was detected in the PHLDA1-silenced clones, as compared to 
Mock and WT cells (Supplementary Fig. 5b). Detection of 
autophagy and apoptosis markers allowed us to correlate both 
processes in the opposite manner in PHLDA1-silenced cells. 
More thorough analysis was carried out further in two selected 
PHLDA1-silenced clones, exhibiting the lowest PHLDA1 
expression level (S6 and S17), to assess the role of PHLDA1 
in the settings of the 14G2a mAb treatment and the cross-
talk between autophagy and apoptosis. Prior to this analysis, 
we verified that there is no difference in ATP levels between 
PHLDA1-silenced (S6 and S17), Mock3, and WT cells grown 
in culture for 48 h, so as the observed results could reflect the 
effects of particular treatment. We observed up-regulation of 
the PHLDA1 protein signal to approximately 1.6 at 48 h after 
the 14G2a mAb treatment in Mock and WT cells and no such a 
trend in PHLDA1-silenced clones (Fig. 5c, d). This attenuated 
effect of the 14G2a mAb on the PHLDA1 level may suggest 
the involvement of the PHLDA1 protein in the 14G2a mAb 
mode of treatment. We revealed that PHLDA1 downregula-
tion modulates levels of several autophagy-associated genes. 
In PHLDA1-silenced CHP-134 cells (S6 and S17), the LC3B 
and ATG12 gene expression on mRNA levels were signifi-
cantly reduced, as compared to Mock3 and WT cells (Fig. 5e). 
The ATG7 and ATG16L mRNA expression levels were also 
decreased in S6 and S17 clones. However, the mRNA expres-
sion of BCN-1 and ATG5 genes was not changed, as com-
pared to Mock3 and WT cells. Initially, this was followed by 
detecting the expression level of some autophagy-associated 
proteins i.e. ATG5, ATG12, and ATG16L in S6 and S17 
clones of PHLDA1-silenced cells (Fig. 5f, g). While the ATG5 
expression level remained unchanged, expression of ATG12 
and ATG16L forms declined in both clones, as compared 
to Mock3 and WT cells. We further described the effect of 
PHLDA1 downregulation on expression of molecules involved 
in autophagy process such as LC3A/B, Beclin-1, and ATG 
proteins in S6 and S17 clones (Fig. 6). Our results showed 
that PHLDA1 is a positive modulator of autophagy, as the 
expression signal of autophagy marker, the LC3A/B-II is 
decreased with statistical significance to 0.1 in S6 and 0.3 
in S17 PHLDA1-silenced clones, as compared to the control 
(Mock3) and WT cells (Fig. 6a, i). Also signals of LC3A/B-I, 
ATG7, and ATG3 proteins are reduced in range of 0.4–0.6 
(Fig. 6b–d, i), and only marginal changes or slight increase in 
P62 and Beclin-1 expression levels were observed (Fig. 6e, f, 
i). However, it must be emphasized that the role of PHLDA1 
may not be limited only to autophagy modulation, as shown 
by detection of expression of the key apoptosis proteins in our 
model. Detection of apoptosis-associated molecules showed 
that the signal of expression of the cleaved caspase 3 increased 
twofold and 2.6-fold, respectively in S6 and S17 clones with 
statistical significance, as compared to Mock3 and WT cells 
(Fig. 6g, i). This change was parallel to an increase in signals 
of the cleaved PARP form in S6 and S17 clones to 1.5 and 1.3, 
respectively (Fig. 6h, i). Significant induction of caspase 3/7 
activities to approximately 2 was also observed in both clones, 
as compared to Mock3 and WT cells (Fig. 6j). Therefore, we 
confirmed that PHLDA1 protein is able to negatively regu-
late apoptosis in CHP-134. The presented results show that 
PHLDA1 is involved in regulation of autophagy- and apopto-
sis-associated proteins and both processes exist in a mutually 
exclusive manner in PHLDA1-silenced CHP-134 cells.
Autophagy detection in MK‑5108‑treated IMR‑32 
cells
Previously we have shown that the aurora A kinase small-
molecule, specific inhibitor, MK-5108, combined with the 
GD2 specific 14G2a mAb significantly enhances cytotoxic 
effect against IMR-32 and CHP-134 cell cultures [11]. 
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Therefore, we also investigated the potential of MK-5108 
inhibitor in the regulation of autophagy in IMR-32 neuro-
blastoma cells. We measured relative expression level of 
autophagy-associated genes in the MK-5108-treated IMR-32 
cells at 48 h (Fig. 7a). We observed significant inhibition of 
the BCN-1 and ATG12 genes to 0.8 and 0.7, respectively and 
no changes in expression levels of LC3B and ATG5 genes. 
Importantly, MK-5108 treatment significantly induced the 
expression of the crucial autophagy marker (LC3A/B), as 
demonstrated here by up-regulation of the signal of the 
converted, autophagosome-associated LC3A/B-II form to 
1.9 (Fig. 7b, c). We monitored autophagic flux by assess-
ing the relative LC3A/B-II expression level measured by 
western blot (Fig. 7e–g). In fact, we observed LC3A/B-II 
estimated autophagic flux induced to approximately 2 by 
MK-5108 at 48 and 72 h, as compared to control cells. Next, 
Fig. 5  PHLDA1 downregula-
tion in CHP-134 cells and its 
consequences on autophagy-
associated transcripts and 
proteins. a The mRNA levels of 
PHLDA1 gene were measured 
by RT-qPCR in PHLDA1-
silenced (S5, S6, S16, and 
S17), Mock1–3, and WT cells. 
RPS13 cDNA was used as the 
reference. The PHLDA1 gene 
mRNA expression in WT cells 
equals 1 (black baseline). b The 
PHLDA1 protein expression 
was measured in PHLDA1-
silenced (S5, S6, S16, and 
S17), Mock1–3 and WT cells 
by western blot at 48 h and 
normalized to α-tubulin. Below 
the chart representative blots are 
presented. c Relative expres-
sion of the PHLDA1 protein in 
PBS-treated and in the 14G2a 
mAb-treated selected PHLDA1-
silenced clones (S6, S17), 
Mock3 and WT cells. Mean 
values for the 14G2a mAb-
treated CHP-134 are presented 
as grey bars and calculated ver-
sus control values (white bars) 
for WT cells (black baseline). 
d Representative immunoblots 
are presented. C—control, 
PBS-treated cells; 14G2a—the 
14G2a mAb-treated cells. e 
The mRNA levels of the LC3B, 
ATG7, BCN-1, ATG16L, ATG5 
and ATG12 genes were meas-
ured by RT-qPCR in PHLDA1-
silenced (S6 and S17), Mock3, 
and WT cells at 48 h. f The 
ATG5, ATG12, and ATG16L 
protein expression levels were 
measured in PHLDA1-silenced 
(S6 and S17), Mock3 and WT 
cells at 48 h by western blot. 
g Representative immunoblots 
are presented. P-values for t 
test were as follow: *p < 0.05, 
**p < 0.01, ***p < 0.001
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IMR-32 cells were pre-treated with CQ and subsequently 
treated with MK-5108 or DMSO. We observed LC3A/B-II 
estimated autophagic flux affected by the CQ and MK-5108 
combined treatment, as demonstrated by the further increase 
in the LC3A/B-II level to 11.4 (48 h) and 12.3 (72 h), that is 
prevented from degradation in autophagolysosomes by CQ 
(Fig. 7e–g). We also measured the CYTO-ID dye-estimated 
autophagic flux in IMR-32 cells (Fig. 7h). MK-5108 and CQ 
combined treatment indicates that autophagic flux is affected 
in IMR-32 cells as the fluorescence intensity of CYTO-ID is 
significantly increased to 7.6 when treated with both agents 
for 48 h, as compared to control or single agent-treated IMR-
32 cells (Fig. 7h). We also checked LC3A/B-II-estimated 
autophagy after treatment with MK-5108 and Baf or both 
agents used alone (Fig. 7k, l). The use of such combination 
confirmed autophagy induction in MK-5108-treated IMR-
32 cells, as the signal of LC3A/B-II form rose further to 
2.3 in case of double treatment, as compared to MK-5108 
(1.6) and Baf (2.0) used alone. Then, the cells were stained 
with CYTO-ID and Hoechst 33342, fixed and visualized 
under fluorescence microscope (Fig. 8). We observed by far 
the greatest CYTO-ID fluorescence signal for combination 
Fig. 6  Effects of stable silenc-
ing of the PHLDA1 gene on 
expression of autophagy and 
apoptosis-associated proteins 
in the 14G2a mAb-treated 
CHP-134 clones. Relative 
expression of LC3A/B-II (a), 
LC3A/B-I (b), ATG7 (c), 
ATG3 (d), P62 (e), Beclin-1 
(f), cleaved caspase 3 (g), and 
cleaved PARP (h) proteins was 
assessed in selected PHLDA1-
silenced (S6, S17), Mock3, and 
WT cells. Mean values for the 
14G2a mAb-treated CHP-134 
are presented as grey bars and 
calculated versus control values 
(white bars) for WT cells (black 
baseline). i Representative 
immunoblots are presented. j 
Relative activities of caspase 
3 and 7 were calculated as 
caspase 3 and 7 activities at day 
3 after treatment and divided 
by caspase 3 and 7 activities 
at day 1 in PHLDA1-silenced 
(S6, S17), Mock3 cells, and 
calculated versus control values 
for WT cells (black baseline). 
P-values for t test were as fol-
low: *p < 0.05
ATG7
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of MK-5108 and CQ. All the results presented so far pro-
vide first-hand evidence that MK-5108 inhibitor induces 
autophagy process in IMR-32 cells. Similar set of experi-
ments was performed for CHP-134 cells (Supplementary 
Fig. 6a–i). We were able to state that also in CHP-134 cell 
line, MK-5108 inhibitor stimulates autophagic flux, as 
demonstrated by increase in LC3A/B-II protein expression 
level signals to 1.4 (at 48 h) and 2.0 (at 72 h) (Supplemen-
tary Fig. 6e). While addition of CQ in combination with 
MK-5108 inhibitor, significantly increased LC3A/B-II level 
signals to further extent (3.4 for 48 h and 4.6 for 72 h), as 
compared to both agents used alone (Supplementary Fig. 6e, 
g, h). These results were further supported by evidence that 
P62 autophagic marker protein is degraded at 72 h in MK-
5108-treated cells and the signal of the expression level of 
P62 was markedly decreased to 1.6 in MK-5108 and CQ-
treated cells, as compared to CQ monotherapy (1.8), indicat-
ing an actual induction of autophagy in CHP-134 cells (Sup-
plementary Fig. 6f, h). To further confirm these results, the 
autophagic compartments were stained with the CYTO-ID 
dye and visualized by fluorescent microscopy (Supplemen-
tary Fig. 6i). We observed an increase in the CYTO-ID dye 
fluorescence signal in MK-5108 treated cells to 1.3, as com-
pared to the control cells. Furthermore, we demonstrated 
that the fluorescence signal of autophagic compartments was 
by far the greatest for the combination of MK-5108 and CQ, 
as compared to the control cells. It was elevated to 2.5 for the 
combination treatment and exceeded the fluorescence signal 
observed for CQ-treated cells (2.0), providing that induction 
of autophagy is present in these cells.
Discussion
The role of autophagy and its regulation in cancer cells 
continues to emerge. Therefore, an increased understanding 
of autophagy in neuroblastoma is important for its optimal 
exploitation for therapeutic advantage. Although important 
strides have been made, several key issues remain unre-
solved, including how autophagy is regulated in neuro-
blastoma tumor cells, the interplay between autophagy and 
apoptosis, and the specific mechanism by which autophagy 
may confer treatment resistance. The purpose of this study 
was to further investigate the molecular and cellular mecha-
nisms of the cytotoxic effect of the 14G2a mAb on human 
neuroblastoma cell survival in vitro, especially in the context 
of autophagy regulation. We aimed to establish how treat-
ment with the 14G2a mAb affects the functional status of 
autophagy in IMR-32 and CHP-134 cells.
Many proteins and molecular pathways, deregulated 
upon the anti-GD2 ganglioside 14G2a mAb treatment, 
such as inhibition of PI3K/AKT/mTOR signaling [30], 
suggested the possible induction of autophagy in IMR-32 
and CHP-134 cells. Several experimental data gathered by 
us in this study demonstrated that autophagy is induced in 
response to the 14G2a mAb treatment in IMR-32 neuro-
blastoma cell line and therefore accounts for a crucial pro-
cess, which may, next to apoptosis, dictate cell fate. How-
ever, the mechanism underlying activation of autophagy 
by binding the 14G2a mAb to GD2 ganglioside still 
remains unresolved. Only recently, reports are emerging 
that a glycosfingolipid—GD3 ganglioside, component of 
cell membranes, is involved in autophagosome formation 
and maturation in human and murine primary fibroblasts 
[35]. The results suggest that gangliosides through their 
interaction with autophagy-associated molecules, could 
be recruited to autophagosomes and contribute to mor-
phogenic remodeling of autolysosomes. Furthermore, cur-
rent literature supports the understanding that ceramide-
induced autophagy functions to promote cell death, either 
through the induction of autophagy or by “switching off” 
autophagy and inducing apoptosis through the CAPN/
calpin-mediated cleavage of ATG5 and/or DISC formation 
[36–38]. We have previously shown that chloroquine, an 
inhibitor of lysosomal degradation, did not rescue IMR-32 
cells from antibody-induced cell death suggesting lack of 
ceramide involvement in the observed effect of the 14G2a 
mAb [6].
To meet expectations of proposing more effective immu-
notherapeutic strategy of neuroblastoma, we studied the role 
of autophagy process in the 14G2a mAb-treated IMR-32 
Fig. 7  Autophagy in MK-5108-treated IMR-32 cells. a Relative 
gene expression level of LC3B, BCN-1, ATG12, and ATG5 in MK-
5108-treated IMR-32 cells (0.1  μM) as compared to the control 
(DMSO-treated cells) assessed at 48  h by RT-qPCR. RPS13 cDNA 
was used as the reference. b Relative protein expression level of 
Beclin-1, ATG3, LC3A/B-I, LC3A/B-II, ATG7, ATG12, ATG16L, 
and ATG5 was measured at 48 h by western blot and normalized to 
α-tubulin. Expression of proteins and their respective genes in control 
cells equals 1 (black baseline). c Representative immunoblots are pre-
sented. d Relative LC3A/B-I expression level affected by MK-5108 
or/and CQ treatment assessed by western blot. IMR-32 cells were 
pre-treated with 10 μM CQ for 1.5 h and subsequently treated with 
0.1  μM MK-5108 or DMSO (control, inhibitor solvent) for 48 and 
72 h. e LC3A/B-II—estimated autophagy flux affected by MK-5108 
or/and CQ treatment assessed by western blot. f, g Representative 
immunoblots are presented. h CYTO-ID—estimated autophagy flux 
in IMR-32 cells. Relative mean fluorescence intensity of the CYTO-
ID dye was measured at 24, 48 h and 72 h using a microplate reader 
and divided by the ATP level signals of the respective groups of 
cells. i Relative mean fluorescence intensity of the CYTO-ID-stained 
autophagic compartments was quantified in five randomly selected 
photomicrographs (taken using ×40 objective). Relative LC3A/B-I 
(j) and LC3A/B-II (k) expression levels affected by MK-5108 or/and 
Baf treatment assessed by western blot. IMR-32 cells were pre-treated 
with 16  nM Baf for 1.5  h and subsequently treated with 0.1  μM 
MK-5108 or DMSO for 48 h. l Representative immunoblots are pre-
sented. C—control, DMSO-treated cells; MK—MK-5108-treated 
cells; CQ—chloroquine-treated cells; Baf—bafilomycin A1-treated 
cells. P-values for t test were as follow: *p < 0.05, **p < 0.01
◂
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neuroblastoma cells. We were able to show that interfering 
with autophagy at an early step by ATG silencing and a late 
step by using bafilomycin A1, augments the 14G2a mAb-
induced apoptosis in IMR-32 cells. Our next goal was to 
define the role of the autophagy process in the 14G2a mAb-
induced neuroblastoma cell killing, that may be either pro- or 
anti-tumor depending upon a cell line or a drug used. Hence, 
autophagy inhibitors such as chloroquine or bafilomycin A1 
were tested to find the most effective combinatorial treat-
ment with the 14G2a mAb. Combined treatment of IMR-32, 
CHP-134 and LAN-5 cells with the 14G2a mAb and either 
CQ or Baf showed potentiating of cytotoxic effects as com-
pared to monotherapy with CQ or Baf, however in all cell 
lines tested, the combination of the 14G2a mAb and CQ or 
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Baf was no more potent than the 14G2a mAb used alone for 
majority of concentrations used. It needs to be emphasized 
that effects of autophagy inhibition may be influenced by a 
few factors including the differences in an autophagy inhibi-
tor, type of target cells, and/or degree of damage on target 
cells. Therefore, other specific inhibitors of autophagy such 
as 3-methyladenine (3-MA) and  NH4Cl need to be tested in 
future and on other neuroblastoma cell lines. It is likely that 
these studies allow for better understanding of the mecha-
nisms of the interplay between autophagy inhibitors and the 
14G2a mAb that dictate a fate of neuroblastoma cells.
Previously we have shown that IMR-32 cells in response 
to the 14G2a mAb and the aurora A kinase specific inhibi-
tor, MK-5108, undergo intensified cell death as compared 
to MK-5108 used alone [11]. In this study, we also pre-
sented evidence that MK-5108 induces autophagy process 
in IMR-32 and CHP-134 neuroblastoma cells. Recent find-
ings show that in breast cancer depletion of aurora A by 
siRNA or chemical inhibition of aurora A by the small mol-
ecule VX-680 increased both the level of LC3-II and the 
number of autophagosomes. Conversely, overexpression 
of aurora A inhibited autophagy, as assessed by decreased 
LC3-II levels [39]. Moreover, the reports are emerging that 
another selective aurora A kinase inhibitor, Alisertib (ALS), 
exerts pro-autophagic effects on A375 and SK-MEL-5 mela-
noma cells by inhibiting P38 MAPK signaling. SB202190, 
a P38 MAPK-selective inhibitor, enhanced ALS-induced 
autophagy in both cell lines [40]. Moreover, ALS inhibi-
tor was shown to induce autophagy in MCF7 and MDA-
MB-231 cells via P38 MAPK [41]. Furthermore, entrectinib, 
small molecule inhibitor of major neuroblastoma patho-
genic marker—anaplastic lymphoma kinase (ALK), exerts 
pro-autophagic effects on SH-SY5YF1174L neuroblastoma 
cells [42]. Abrogation of autophagy by chloroquine signifi-
cantly increased the toxicity of entrectinib, as confirmed by 
enhanced death rate in SH-SY5YF1174L cells.
Our study also addressed a question if autophagy process 
may participate in the 14G2a-mediated cell death, manifest-
ing itself especially in cells, in which apoptosis is not pre-
sent. Therefore, we assessed the relevance of autophagy in 
non-apoptotic setting in CHP-134 cells. On the basis of vari-
ous published findings and a set of our experiments, it was 
fairly justifiable to anticipate induction of autophagy in the 
14G2a mAb-treated CHP-134 cells. However, this scenario 
was ruled out as autophagy is not enhanced beyond constitu-
tive level after the 14G2a mAb treatment of CHP-134 cells. 
There are several findings showing that enhancement of 
autophagy may potentiate cell death in some models. Induc-
ing autophagy with its activators may be alternative strategy 
worth exploring in CHP-134 cells. Findings described in 
[31] show that induction of autophagy can accelerate cyto-
toxic effects of chLym-1, a chimeric anti-human HLA-DR 
monoclonal antibody on Raji lymphoma cells. It was found 
that the viability of Raji cells treated with the chLym-1 and 
an autophagy activator, rapamycin, was significantly inhib-
ited, as compared with that of the Raji cells treated with 
chLym-1 alone. While cells treated with chLym-1 in combi-
nation with autophagy inhibitors 3-MA and  NH4Cl showed 
a significant rescue of cell viability after 48 h of co-incuba-
tion, 3-MA and  NH4Cl alone have no significant effect on 
viability of Raji cells [31]. Other studies also revealed that 
inhibition of mTOR complex and enhancement of autophagy 
is involved in growth inhibition, apoptotic cell death in lym-
phoma cells, and may correlate with greater clinical out-
come, suggesting a tumor-suppression role of autophagy in 
non-Hodgkin’s lymphoma treatment [43].
Lysosomal cell death, which could be yet another form of 
cell death involved in the observed effect of the 14G2a mAb, 
needs to be examined. It is initiated by lysosomal membrane 
permeabilization (LMP), which leads to the release of cath-
epsins and other hydrolases from the lysosomal lumen to the 
cytosol [44]. Depending on the extent of LMP and the cell 
type, LMP can result in apoptosis featuring caspase activa-
tion and mitochondrial outer membrane permeabilization or 
necrosis-like programmed cell death [45]. There are vari-
ous stimuli that can trigger LMP, e.g., lysosomotropic com-
pounds with detergent-like activity such as chloroquine [46]. 
LMP type of cell death will be further studied especially in 
apoptotic and non-apoptotic settings.
Interestingly, the evidence appeared on how the PHLDA1 
protein might act as a mediator of both autophagy and apop-
tosis. The PHLDA1 gene was reported to be up-regulated 
in both autophagy and apoptosis and silencing of this gene 
was found to reduce both activities, strongly suggesting that 
PHLDA1 mediates and positively regulates both autophagy 
and apoptosis pathways in T-47D breast carcinoma cells 
[34]. Therefore, we aimed to determine autophagy and apop-
tosis-linked biological function of PHLDA1 in CHP-134 
cells. We followed PHLDA1-silencing approach in CHP-
134 cells to explain molecular relationships and the circum-
stances that potentially could dictate the choice between 
apoptosis and autophagy in CHP-134 cells. Our results 
showed that PHLDA1 is a positive modulator of autophagy 
and both processes exist in a mutually exclusive manner 
in the PHLDA1-silenced CHP-134 cells. These results are 
contrary to our previous results in IMR-32 cells, where the 
function of PHLDA1 pointed to inhibition of autophago-
somes formation and higher susceptibility to apoptosis [21]. 
Further studies are warranted to determine the perplexing 
role of PHLDA1 which, as it is implicated in many studies, 
relies on cell-specific environment [33].
It is still not clear whether and how autophagy may influ-
ence response of cancer cells to therapeutic agents. There 
is only little evidence that immunological mechanisms 
(ADCC, CDC) and apoptosis process induced by different 
chemotherapeutics are accompanied by autophagy process 
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in cancer cells [31]. This broader context of interpretation 
of cell death mechanisms should be thoroughly considered 
to improve the efficacy of drugs used.
The need for defining optimal strategies to modulate 
autophagy for therapeutic advantage is still in its infancy. 
The combination of immune-based drugs i.e., mAb with 
autophagy modulators can broaden the treatment options of 
neuroblastoma. Targeting various molecular processes and 
pathways, instead of one, with drug combinations represents 
a new challenge in the coming decade but is of great prom-
ise. Innovative treatment strategies based on a better under-
standing of the crucial biological processes and pathways 
responsible for neuroblastoma initiation and progression 
display its potential in improvement of patients survival.
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Fig. 8  Monitoring of CYTO-
ID dye fluorescence signal in 
autophagy compartments in 
IMR-32 cells. Localization of 
the CYTO-ID and Hoechst 
33342 fluorescence dyes in 
IMR-32 cells was assessed 
using fluorescence microscope. 
IMR-32 cells were pre-treated 
with 10 μM CQ for 1.5 h and 
subsequently treated with 
0.1 μM MK-5108 or DMSO 
for 48 h. The cells were then 
stained with CYTO-ID and 
Hoechst 33342, fixed, and 
visualized under fluorescence 
microscope. Relative mean 
fluorescence intensity of 
CYTO-ID-stained autophagic 
compartments was quantified in 
five randomly selected photo-
micrographs (taken using a ×40 
objective). Scale bar 25 μm. 
C—control, DMSO-treated 
cells, MK—MK-5108-treated 
IMR-32 cells, CQ—chloro-
quine-treated IMR-32 cells, 
PC—positive control, IMR-32 
cells grown in amino acids-free 
medium for 24 h
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